Natalia Lukashchuk

Natalia Lukashchuk

Auto-generated profile, based on publicly available information

Natalia Lukashchuk

AstraZeneca (United Kingdom) 12 Cambridge

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJoaquin Mateo
Joaquin Mateo
JBJohann S. de Bono
Johann S. de Bono
KFKarim Fizazi
Karim Fizazi
Fred SaadFred Saad
Fred Saad
NSNeil Shore
Neil Shore
MHMaha Hussain
Maha Hussain
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.

26 June 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
NLNatalia Lukashchuk
Natalia Lukashchuk
ABAlan Barnicle
Alan Barnicle
CACarrie A. Adelman
Carrie A. Adelman
JAJoshua Armenia
Joshua Armenia
JKJinyu Kang
Jinyu Kang
EHElizabeth A. Harrington
Elizabeth A. Harrington
Prostate cancer is among the most common diseases worldwide. Despite recent progress with treatments, patients with advanced prostate cancer have poor outcomes and there is a high unmet need in this population. Understanding molecular determinants underlying prostate cancer and the aggressive phenotype of disease can help with design of better clinical trials and improve treatments for these patients. One of the pathways often altered in advanced prostate cancer is DNA damage response (DDR), including alterations in BRCA1/2 and other homologous recombination repair (HRR) genes. Alterations in the DDR pathway are particularly prevalent in metastatic prostate cancer. In this review, we summarise the prevalence of DDR alterations in primary and advanced prostate cancer and discuss the impact of alterations in the DDR pathway on aggressive disease phenotype, prognosis and the association of germline pathogenic1 alterations in DDR genes with risk of developing prostate cancer.

20 April 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
GSGiovanni Scambia
Giovanni Scambia
RVRicardo Villalobos Valencia
Ricardo Villalobos Valencia
NCNicoletta Colombo
Nicoletta Colombo
DCDavid Cibula
David Cibula
CICharles Leath III
Charles Leath III
RPRichard T. Penson
Richard T. Penson
Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020 ). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis. Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). OS was similar with olaparib versus chemotherapy (hazard ratio [HR], 1.07 [95% CI, 0.76 to 1.49]; P = .71, median 34.9 and 32.9 months, respectively, full analysis set). OS with olaparib was favorable in patients with two previous chemotherapy lines (HR, 0.83 [olaparib v chemotherapy] [95% CI, 0.51 to 1.38]; median 37.9 v 28.8 months); however, a potential detrimental effect was seen in patients with at least three previous chemotherapy lines (HR, 1.33 [95% CI, 0.84 to 2.18]; median 29.9 v 39.4 months). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.

9 August 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
NTNadine Tung
Nadine Tung
RHRobert Hollis
Robert Hollis
GVGiuseppe Viale
Giuseppe Viale
CTCarol Tweed
Carol Tweed
NLNatalia Lukashchuk
Natalia Lukashchuk
MBMichael Birrer
Michael Birrer
Individuals with pathogenic variants in the BRCA1 or BRCA2 genes have an increased risk of developing breast, ovarian, pancreatic, and prostate cancers. BRCA variants can be of germline origin (ie, inherited) or arise spontaneously during tumor development (ie, somatic). Germline BRCA mutation status is determined by analyzing DNA from nontumor cells in blood or saliva. Tumor BRCA tests detect both germline and somatic BRCA mutations in tumor DNA, and somatic BRCA mutation status is determined when the tumor BRCA test is positive and the germline BRCA test is negative. BRCA1/BRCA2 inactivation results in homologous recombination deficiency, which sensitizes tumor cells with BRCA mutation to poly(ADP-ribose) polymerase (PARP) inhibitors. Thus, timely determination of BRCA status in patients with cancer can help guide optimal disease management. PARP inhibitors are approved across a range of treatment settings for several tumor types, as monotherapy or in combination, as well as in biomarker selected and unselected populations. For patients with human epidermal growth factor receptor 2-negative breast cancer and germline BRCA mutation (United States, European Union, and other markets) or germline or somatic BRCA mutation (Japan), PARP inhibitors are approved in early adjuvant (olaparib) and metastatic (olaparib, talazoparib) settings. Emerging evidence now suggests possible biological similarities in breast tumors with germline BRCA mutation and somatic BRCA mutation, with preclinical and translational data demonstrating that both can result in high levels of biallelic inactivation, homologous recombination deficiency phenotypes, and PARP inhibitor sensitivity. There is also evidence from clinical trials demonstrating the benefit of PARP inhibitor therapy in patients with somatic BRCA–mutated breast cancer, suggesting that the inclusion criteria of more trials should be expanded to include patients with somatic BRCA mutation.

29 May 2026 in Cancer Research Communications
Verified
Journal Article
Open access
RARahul Aggarwal
Rahul Aggarwal
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
SDSusan M. Domchek
Susan M. Domchek
OGOscar Goodman
Oscar Goodman
SPSophie Postel-Vinay
Sophie Postel-Vinay
WAWassim Abida
Wassim Abida
Purpose: Ceralasertib is an oral ataxia telangiectasia and Rad3-related (ATR) inhibitor with preclinical activity in ataxia-telangiectasia mutated (ATM)-altered cancers. The phase 2a PLANETTE study evaluated ceralasertib in previously treated advanced solid tumors (Cohort A) or metastatic castration-resistant prostate cancer (Cohort B) with ATM alterations (ATM mutations and/or ATM protein deficiency). Patients and Methods: Patients received ceralasertib 160 mg BID on days 1–14 of a 28-day cycle. Efficacy was evaluated in patients with centrally confirmed ATM alterations. The primary endpoint was objective response rate (ORR; Cohort A) or composite response rate (CRR: radiographic response, PSA response, or circulating tumor cell conversion; Cohort B). Secondary endpoints included progression-free survival (PFS) and safety. Results: Cohorts A and B included 30 and 15 patients, respectively. ORR (Cohort A) was 7.1% (80% confidence interval [CI]: 1.9–17.9; n=2/28): one complete response ongoing at 14.1 months (breast cancer) and one partial response ongoing at 7.4 months (endometrial cancer). CRR (Cohort B) was 7.7% (80% CI: 0.8–28.6; n=1/13). In patients with centrally confirmed ATM protein loss, ORR was 18.2% (80% CI: 4.9–41.5; n=2/11) and CRR was 0% (80% CI: 0–28.0; n=0/7). Median PFS was 3.7 months in each cohort (Cohort A, 80% CI: 1.9–5.6; Cohort B, 80% CI: 1.9–not calculable). Grade ≥3 AEs occurred in 50.0% of Cohort A and 53.3% of Cohort B patients. The most common AEs overall were asthenia/fatigue, nausea, and anemia. Conclusions: Ceralasertib monotherapy was tolerated; however, responses were limited. Alternative patient selection and combination treatments are being explored.

2 July 2026
Verified
Other
Open access
RARahul Aggarwal
Rahul Aggarwal
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
SDSusan M. Domchek
Susan M. Domchek
OGOscar Goodman
Oscar Goodman
SPSophie Postel-Vinay
Sophie Postel-Vinay
WAWassim Abida
Wassim Abida
MRI scan showing target lesion reduction in the responder with endometrial cancer receiving ceralasertib 160 mg BID in Cohort A